

Mats Jerkeman  
Lymfom - Klinisk forskning  
LUCC: Lunds universitets cancercentrum  
Sektion I  
Onkologi övergripande  
Medicinsk onkologi  
**Adresstyp: Postadress.**  
Lunds Universitet, Box 117  
221 00  
Sverige  
**Adresstyp: Besöksadress.**  
Barnngatan 4, SUS  
22185  
Lund  
Sverige  
**Adresstyp: Postadress.**  
Universitetssjukhuset, SUS  
221 85  
Lund  
Sverige  
**E-post:** mats.jerkeman@med.lu.se  
**Mobil:** +46704973507  
**Telefon:** +4646177827



## Forskning

Maligna lymfom är tumörer utgående från immunsystemet. De innefattar ca 50 olika undergrupper med vitt skilda kliniska förlopp. Vår grupp har sedan många år bedrivit forskning angående kring samtliga aspekter av lymfom: studier av tumörbiologin med immunhistokemiska och molekylärbioologiska metoder, utveckling av diagnostik, samt populationsbaserade studier utgående från det Svenska Lymfomregistret. Unikt i Sverige är att vi också kunnat initiera egna kliniska prövningar med nya läkemedel för lymfombehandling.

## Anställning

### Projektledare

Lymfom - Klinisk forskning  
Lunds universitet  
Sverige  
2016 okt. 13 → present

### Principal Investigator

LUCC: Lunds universitets cancercentrum  
Lunds universitet  
Sverige  
2020 feb. 10 → present

### Sektionschef

Sektion I  
Lunds universitet  
Sverige  
2020 maj 4 → present

### Avdelningschef

Onkologi övergripande  
Lunds universitet  
Lund, Sverige  
2020 maj 4 → present

**Avdelningschef, Professor,Handledare**

Medicinsk onkologi  
Lunds universitet  
Lund, Sverige  
2020 maj 4 → present

#### **Chairman**

2019 nov. 6 → present

#### **Editor, ESMO Guidelines**

European Society of Medical Oncology (ESMO)  
Schweiz  
2019 jan. 1 → present

#### **Chairman, Mantle cell lymphoma**

2015 juni 1 → present

#### **Ordförande**

Swedish Lymphoma Group  
Sverige  
2014 jan. 14 → present

## **Forskningsoutput**

### **Nationwide Assessment of Patient Trajectories in Mantle Cell Lymphoma: The Swedish MCL complete Project**

Jerkeman, M., Ekberg, S., Glimelius, I., Albertsson-Lindblad, A., Entrop, J. P., Ellin, F., Sonnevi, K., Lewerin, C., Brandefors, L. & Smedby, K. E., 2023 aug., I: HemaSphere. 7, 8, s. E928

### **Late effects in patients with mantle cell lymphoma treated with or without autologous stem cell transplantation**

Ekberg, S., Smedby, K. E., Albertsson-Lindblad, A., Jerkeman, M., Weibull, C. E. & Glimelius, I., 2023 mars 14, I: Blood Advances. 7, 5, s. 866-874 9 s.

### **Exploring new prognostic biomarkers in Mantle Cell Lymphoma: a comparison of the circSCORE and the MCL35 score**

Salim, R., Husby, S., Winther Eskelund, C., Scott, D. W., Holte, H., Kolstad, A., Rätty, R., Ek, S., Jerkeman, M., Geisler, C., Sommer Kristensen, L., Dahl, M. & Grønbaek, K., 2023, I: Leukemia and Lymphoma. 64, 8, s. 1414-1423 10 s.

### **HPV self-sampling versus healthcare provider collection on the effect of cervical cancer screening uptake and costs in LMIC: a systematic review and meta-analysis**

Mekuria, S. F., Timmermans, S., Borgfeldt, C., Jerkeman, M., Johansson, P. & Linde, D. S., 2023, I: Systematic Reviews. 12, 1, 103.

### **Overexpression of the key metabolic protein CPT1A defines mantle cell lymphoma patients with poor response to standard high dose chemotherapy independent of MIPI and complement established high-risk factors**

Sandström Gerdtsen, A., de Matos Rodrigues, J., Eskelund, C. W., Husby, S., Gronbaek, K., Rätty, R., Kolstad, A., Geisler, C. H., Porwit, A., Jerkeman, M. & Ek, S., 2023, I: Haematologica. 108, 4, s. 1092-1104

### **Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study**

Hess, G., Dreyling, M., Oberic, L., Gine, E., Zinzani, P. L., Linton, K., Vilmar, A., Jerkeman, M., Chen, J. M. H., Ohler, A., Stilgenbauer, S., Thieblemont, C., Lambert, J., Zilioli, V. R., Sancho, J. M., Ubieta, A. J., Fischer, L., Eyre, T. A., Keeping, S., Park, J. E., & 5 andraWu, J. J., Siddiqi, R., Reitan, J., Wade, S. & Salles, G., 2023, I: British Journal of Haematology. 202, 4, s. 749-759

### **Tackling Mantle Cell Lymphoma in Europe**

Horgan, D., Walewski, J., Aurer, I., Visco, C., Giné, E., Fetica, B., Jerkeman, M., Kozaric, M., da Silva, M. G. & Dreyling, M., 2022 sep., I: Healthcare (Switzerland). 10, 9, 1682.

### **Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma**

Wang, M. L., Jurczak, W., Jerkeman, M., Trotman, J., Zinzani, P. L., Belada, D., Boccimini, C., Flinn, I. W., Giri, P., Goy, A., Hamlin, P. A., Hermine, O., Hernández-Rivas, J. Á., Hong, X., Kim, S. J., Lewis, D., Mishima, Y., Özcan, M., Perini, G. F., Pocock, C., & 12 andraSong, Y., Spurgeon, S. E., Storrington, J. M., Walewski, J., Zhu, J., Qin, R., Henninger, T., Deshpande, S., Howes, A., Le Gouill, S., Dreyling, M. & the SHINE Investigators, 2022 juni 30, I: *New England Journal of Medicine*. 386, 26, s. 2482-2494 13 s.

### **Impact of comorbidity in older patients with peripheral T-cell lymphoma: an international retrospective analysis of 891 patients**

Mead, M., Cederleuf, H., Bjorklund, M., Wang, X., Relander, T., Jerkeman, M., Gaut, D., Larson, S. & Ellin, F., 2022 apr. 12, I: *Blood Advances*. 6, 7, s. 2120-2128 9 s.

### **High-risk subtypes of chronic lymphocytic leukemia are detectable as early as 16 years prior to diagnosis**

Kolijn, P. M., Hosnijeh, F. S., Späth, F., Hengeveld, P. J., Agathangelidis, A., Saleh, M., Casabonne, D., Benavente, Y., Jerkeman, M., Agudo, A., Barricarte, A., Besson, C., Sánchez, M. J., Chirlaque, M. D., Masala, G., Sacerdote, C., Grioni, S., Schulze, M. B., Nieters, A., Engelfriet, P., & 4 andraHultdin, M., McKay, J. D., Vermeulen, R. C. H. & Langerak, A. W., 2022 mars 10, I: *Blood*. 139, 10, s. 1557-1563 7 s.

### **Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma**

Meriranta, L., Alkopsi, A., Pasanen, A., Lepistö, M., Mapar, P., Blaker, Y. N., Jørgensen, J., Karjalainen-Lindsberg, M. L., Fiskvik, I., Mikalsen, L. T. G., Autio, M., Björkholm, M., Jerkeman, M., Fluge, Ø., Brown, P., Jyrkkiö, S., Holte, H., Pitkänen, E., Ellonen, P. & Leppä, S., 2022 mars, I: *Blood*. 139, 12, s. 1863-1877 15 s.

### **Idelalisib in relapsed/refractory diffuse large B-cell lymphoma: results from a Nordic Lymphoma Group phase II trial**

Fjordén, K., Ekberg, S., Kuric, N., Smedby, K. E., Lagerlöf, I., Larsen, T. S., Jørgensen, J. M., de Nully Brown, P. & Jerkeman, M., 2022 jan., I: *British Journal of Haematology*. 196, 2, s. 437-440 4 s.

### **Advances in immune therapies in hematological malignancies**

Mazzarella, L., Enblad, G., Olweus, J., Malmberg, K. J. & Jerkeman, M., 2022, I: *Journal of Internal Medicine*. 292, 2, s. 205-220

### **Clinical and biological impact of SAMHD1 expression in mantle cell lymphoma**

Merrien, M., Wasik, A. M., Ljung, E., Morsy, M. H. A., de Matos Rodrigues, J., Carlsten, M., Rassidakis, G. Z., Christensson, B., Kolstad, A., Jerkeman, M., Ek, S., Herold, N., Wahlin, B. E. & Sander, B., 2022, I: *Virchows Archiv*. 480, 3, s. 655-666

### **Expression patterns and prognostic potential of circular RNAs in mantle cell lymphoma: a study of younger patients from the MCL2 and MCL3 clinical trials**

Dahl, M., Husby, S., Eskelund, C. W., Besenbacher, S., Fjelstrup, S., Côme, C., Ek, S., Kolstad, A., Rätty, R., Jerkeman, M., Geisler, C. H., Kjems, J., Kristensen, L. S. & Grønbæk, K., 2022, I: *Leukemia*. 36, 1, s. 177-188

### **Outcomes of relapsed/refractory diffuse large B-cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line—A population-based study of 736 patients**

Harrysson, S., Eloranta, S., Ekberg, S., Enblad, G., El-Galaly, T. C., Sander, B., Sonnevli, K., Andersson, P. O., Jerkeman, M. & Smedby, K. E., 2022, I: *British Journal of Haematology*. 198, 2, s. 267-277

### **Patient trajectories after diagnosis of diffuse large B-cell lymphoma—a multistate modelling approach to estimate the chance of lasting remission**

Ekberg, S., Crowther, M., Harrysson, S., Jerkeman, M., E. Smedby, K. & Eloranta, S., 2022, I: *British Journal of Cancer*. 127, 9, s. 1642-1649

### **Pre-treatment health-related quality of life parameters have prognostic impact in patients >65 years with newly diagnosed mantle cell lymphoma: The Nordic Lymphoma Group MCL4 (LENA-BERIT) experience**

Lindberg, Å., Eskelund, C. W., Albertsson-Lindblad, A., Kolstad, A., Laurell, A., Rätty, R., Grønbæk, K., Geisler, C. H. & Jerkeman, M., 2022, I: *Hematological Oncology*. 40, 1, s. 23-31

**Serum proteome modulations upon treatment provides biological insight on response to treatment in relapsed mantle cell lymphoma**

Lokhande, L., Kuci Emruli, V., Eskelund, C. W., Kolstad, A., Hutchings, M., Rätty, R., Niemann, C. U., Grønabæk, K., Jerkeman, M. & Ek, S., 2022, I: *Cancer Reports*. 5, 7

**Survival in mantle cell lymphoma after frontline treatment with R-bendamustine, R-CHOP and the Nordic MCL2 regimen - a real world study on patients diagnosed in Sweden 2007-2017**

Albertsson Lindblad, A., Palsdottir, T., Smedby, K. E., Weibull, C. E., Glimelius, I. & Jerkeman, M., 2022, I: *Haematologica*. 107, 3, s. 740-743

**The EHA Research Roadmap: Malignant Lymphoid Diseases**

Dreyling, M., Jerkeman, M., Salles, G. & et al., 2022, I: *HemaSphere*. 6, 6, s. E726

**American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma**

Munshi, P. N., Hamadani, M., Kumar, A., Dreger, P., Friedberg, J. W., Dreyling, M., Kahl, B., Jerkeman, M., Kharfan-Dabaja, M. A., Locke, F. L., Shadman, M., Hill, B. T., Ahmed, S., Herrera, A. F., Sauter, C. S., Bachanova, V., Ghosh, N., Lunning, M., Kenkre, V. P., Aljurf, M., & 14 andraWang, M., Maddocks, K. J., Leonard, J. P., Kamdar, M., Phillips, T., Cashen, A. F., Inwards, D. J., Sureda, A., Cohen, J. B., Smith, S. M., Carlo-Stella, C., Savani, B., Robinson, S. P. & Fenske, T. S., 2021 sep. 1, I: *Transplantation and cellular therapy*. 27, 9, s. 720-728 9 s.

**How should we use ibrutinib in patients with mantle cell lymphoma?**

Jerkeman, M., 2021 maj 1, I: *British Journal of Haematology*. 193, 3, s. 445-446 2 s.

**Infiltration of CD163-, PD-L1- and FoxP3-positive cells adversely affects outcome in patients with mantle cell lymphoma independent of established risk factors**

Rodrigues, J. M., Nikkarinen, A., Hollander, P., Weibull, C. E., Rätty, R., Kolstad, A., Amini, R. M., Porwit, A., Jerkeman, M., Ek, S. & Glimelius, I., 2021 maj 1, I: *British Journal of Haematology*. 193, 3, s. 520-531 12 s.

**Association between anthropometry and lifestyle factors and risk of B-cell lymphoma: An exposome-wide analysis**

Saberi Hosnijeh, F., Casabonne, D., Nieters, A., Solans, M., Naudin, S., Ferrari, P., McKay, J. D., Benavente, Y., Weiderpass, E., Freisling, H., Severi, G., Boutron Ruault, M. C., Besson, C., Agnoli, C., Masala, G., Sacerdote, C., Tumino, R., Huerta, J. M., Amiano, P., Rodriguez-Barranco, M., & 15 andraBonet, C., Barricarte, A., Christakoudi, S., Knuppel, A., Bueno-de-Mesquita, B., Schulze, M. B., Kaaks, R., Canzian, F., Späth, F., Jerkeman, M., Rylander, C., Tjønneland, A., Olsen, A., Borch, K. B. & Vermeulen, R., 2021, I: *International Journal of Cancer*. 148, 9, s. 2115-2128

**ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma**

Munshi, P. N., Hamadani, M., Kumar, A., Dreger, P., Friedberg, J. W., Dreyling, M., Kahl, B., Jerkeman, M., Kharfan-Dabaja, M. A., Locke, F. L., Shadman, M., Hill, B. T., Ahmed, S., Herrera, A. F., Sauter, C. S., Bachanova, V., Ghosh, N., Lunning, M., Kenkre, V. P., Aljurf, M., & 14 andraWang, M., Maddocks, K. J., Leonard, J. P., Kamdar, M., Phillips, T., Cashen, A. F., Inwards, D. J., Sureda, A., Cohen, J. B., Smith, S. M., Carlo-Stella, C., Savani, B., Robinson, S. P. & Fenske, T. S., 2021, I: *Bone Marrow Transplantation*. 56, 12, s. 2911-2921

**Clinical characteristics and histopathological patterns of hodgkin lymphoma and treatment outcomes at a tertiary cancer center in ethiopia**

Adam, M., Bekueretsion, Y., Abubeker, A., Tadesse, F., Kwiecinska, A., Howe, R., Petros, B., Jerkeman, M. & Gebremedhin, A., 2021, I: *JCO Global Oncology*. 7, s. 277-288 12 s.

Detailed Long-Term Follow-Up of Patients Who Relapsed after the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3  
Eskelund, C. W., Dimopoulos, K., Kolstad, A., Glimelius, I., Rätty, R., Gjerdrum, L. M. R., Sonnevi, K., Josefsson, P., Nilsson-Ehle, H., Bentzen, H. H. N., Fagerli, U. M., Kuittinen, O., Haaber, J., Niemann, C. U., Pedersen, L. B., Larsen, M. T., Geisler, C. H., Hutchings, M., Jerkeman, M. & Grønabæk, K., 2021, (E-pub ahead of print) I: *HemaSphere*.

**Detecting deviations from the efficacy and safety results of single-arm trials using real-world data: The case of a CAR-T cell therapy in B-cell lymphoma**

Jakobsen, L. H., Callréus, T., Sessa, M., Jerkeman, M., Andersen, M. & El-Galaly, T. C., 2021, I: *Pharmacoepidemiology and Drug Safety*.

**EHA/ESMO Clinical Practice Guidelines for the Management of Malignant Lymphoma: Recommendations for the Second Phase of the COVID-19 Pandemic**

Dreyling, M., Aurer, I., Federico, M., Jerkeman, M., Kersten, M. J., Linton, K., Mey, U., Tilly, H. & Buske, C., 2021, I: *HemaSphere*. 5, 2, s. e529

**Incidence of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden**

Harrysson, S., Eloranta, S., Ekberg, S., Enblad, G., Jerkeman, M., Wahlin, B. E., Andersson, P. O. & Smedby, K. E., 2021, I: *Blood Cancer Journal*. 11, 1, 9.

**Myocardial infarction in diffuse large B-cell lymphoma patients – a population-based matched cohort study**

Ekberg, S., Harrysson, S., Jernberg, T., Szummer, K., Andersson, P. O., Jerkeman, M., Smedby, K. E. & Eloranta, S., 2021, I: *Journal of Internal Medicine*. 290, 5, s. 1048-1060

**Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up**

Dreyling, M., Ghielmini, M., Rule, S., Salles, G., Ladetto, M., Tonino, S. H., Herfarth, K., Seymour, J. F., Jerkeman, M. & ESMO Guidelines Committee, 2021, I: *Annals of oncology : official journal of the European Society for Medical Oncology*. 32, 3, s. 298-308 11 s.

**Targeted genomic investigations in a population-based cohort of mantle cell lymphoma reveal novel clinically relevant targets**

Rodrigues, J. M., Porwit, A., Hassan, M., Ek, S. & Jerkeman, M., 2021, I: *Leukemia and Lymphoma*. 62, 11, s. 2637-2647 11 s.

**Unmarried or less-educated patients with mantle cell lymphoma are less likely to undergo a transplant, leading to lower survival**

Glimelius, I., Smedby, K. E., Albertsson-Lindblad, A., Crowther, M. J., Eloranta, S., Jerkeman, M. & Weibull, C. E., 2021, I: *Blood Advances*. 5, 6, s. 1638-1647 10 s.

**p53 is associated with high-risk and pinpoints TP53 missense mutations in mantle cell lymphoma**

Rodrigues, J. M., Hassan, M., Freiburghaus, C., Eskelund, C. W., Geisler, C., Rätty, R., Kolstad, A., Sundström, C., Glimelius, I., Grønbaek, K., Kwiecinska, A., Porwit, A., Jerkeman, M. & Ek, S., 2020 dec., I: *British Journal of Haematology*. 191, 5, s. 796-805 10 s.

**Healthy lifestyle and the risk of lymphoma in the European Prospective Investigation into Cancer and Nutrition study**

Naudin, S., Solans Margalef, M., Saberi Hosnijeh, F., Nieters, A., Kyrø, C., Tjønneland, A., Dahm, C. C., Overvad, K., Mahamat-Saleh, Y., Besson, C., Boutron-Ruault, M. C., Kühn, T., Canzian, F., Schulze, M. B., Peppas, E., Karakatsani, A., Trichopoulou, A., Sieri, S., Masala, G., Panico, S., & 21 andraTumino, R., Ricceri, F., Chen, S. L. F., Barroso, L. L., Huerta, J. M., Sánchez, M. J., Ardanaz, E., Menéndez, V., Amiano Exezarreta, P., Spaeth, F., Jerkeman, M., Jirstrom, K., Schmidt, J. A., Aune, D., Weiderpass, E., Riboli, E., Vermeulen, R., Casabonne, D., Gunter, M., Brennan, P. & Ferrari, P., 2020 sep. 15, I: *International Journal of Cancer*. 147, 6, s. 1649-1656 8 s.

**Outcome and determinants of failure to complete primary R-CHOP treatment for reasons other than non-response among patients with diffuse large B-cell lymphoma**

Wåsterlid, T., Harrysson, S., Andersson, T. M. L., Ekberg, S., Enblad, G., Andersson, P. O., Jerkeman, M., Eloranta, S. & Smedby, K. E., 2020 juli, I: *American Journal of Hematology*. 95, 7, s. 740-748 9 s.

**Trends in the prevalence, incidence and survival of non-Hodgkin lymphoma subtypes during the 21st century – a Swedish lymphoma register study**

Ekberg, S., E. Smedby, K., Glimelius, I., Nilsson-Ehle, H., Goldkuhl, C., Lewerin, C., Jerkeman, M. & Eloranta, S., 2020 juni, I: *British Journal of Haematology*. 189, 6, s. 1083-1092 10 s.

**Clonal hematopoiesis evolves from pretreatment clones and stabilizes after end of chemotherapy in patients with MCL**  
Eskelund, C. W., Husby, S., Favero, F., Klausen, T. W., Rodriguez-Gonzalez, F. G., Kolstad, A., Pedersen, L. B., Råty, R. K., Geisler, C. H., Jerkeman, M., Weischenfeldt, J. & Grønbaek, K., 2020 maj 28, I: *Blood*. 135, 22, s. 2000-2004 5 s.

**Detection of HPV mRNA in Self-collected Vaginal Samples Among Urban Ethiopian Women**  
Mekuria, S., Jerkeman, M., Forslund, O., Fikru, S. & Borgfeldt, C., 2020 mars, I: *Anticancer research*. 40, 3, s. 1513-1517

**Inflammatory potential of diet and risk of lymphoma in the European Prospective Investigation into Cancer and Nutrition**  
Solans, M., Benavente, Y., Saez, M., Agudo, A., Jakszyn, P., Naudin, S., Hosnijeh, F. S., Gunter, M., Huybrechts, I., Ferrari, P., Besson, C., Mahamat-Saleh, Y., Boutron-Ruault, M. C., Kühn, T., Kaaks, R., Boeing, H., Lasheras, C., Sánchez, M. J., Amiano, P., Chirlaque, M. D., & 26 andra Ardanaz, E., Schmidt, J. A., Vineis, P., Riboli, E., Trichopoulou, A., Karakatsani, A., Valanou, E., Masala, G., Agnoli, C., Tumino, R., Sacerdote, C., Mattiello, A., Skeie, G., Weiderpass, E., Jerkeman, M., Dias, J. A., Späth, F., Nilsson, L. M., Dahm, C. C., Overvad, K., Petersen, K. E. N., Tjønneland, A., de Sanjose, S., Vermeulen, R., Nieters, A. & Casabonne, D., 2020 mars, I: *European Journal of Nutrition*. 59, 2, s. 813-823 11 s.

**An international multicenter retrospective analysis of patients with extranodal marginal zone lymphoma and histologically confirmed central nervous system and dural involvement**  
Sunderland, A. J., Steiner, R. E., Al Zahrani, M., Pinnix, C. C., Dabaja, B. S., Gunther, J. R., Nastoupil, L. J., Jerkeman, M., Joske, D., Cull, G., El-Galaly, T., Villa, D. & Cheah, C. Y., 2020, I: *Cancer Medicine*. 9, 2, s. 663-670 8 s.

**Immune-related protein signature in serum stratify relapsed mantle cell lymphoma patients based on risk**  
Lokhande, L., Kuci Emruli, V., Kolstad, A., Hutchings, M., Råty, R., Jerkeman, M. & Ek, S., 2020, I: *BMC Cancer*. 20, 1, 1202.

**National e-library for standardized chemotherapy regimens**  
Fyhr, A., Borell, J., Jerkeman, M. & Ek, Å., 2020, I: *Acta Oncologica*. 59, 9, s. 1079-1083 5 s.

**Comorbidities and sex differences in causes of death among mantle cell lymphoma patients – A nationwide population-based cohort study**  
Glimelius, I., Smedby, K. E., Eloranta, S., Jerkeman, M. & Weibull, C. E., 2019 nov. 13, I: *British Journal of Haematology*.

**Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide**  
Albertsson-Lindblad, A., Freiburghaus, C., Jerkeman, M. & Ek, S., 2019 aug. 6, I: *Experimental Hematology and Oncology*. 8, 1, 16.

**Relapse Risk and Loss of Lifetime After Modern Combined Modality Treatment of Young Patients With Hodgkin Lymphoma: A Nordic Lymphoma Epidemiology Group Study**  
Biccler, J. L., Glimelius, I., Eloranta, S., Smeland, K. B., Brown, P. D. N., Jakobsen, L. H., Frederiksen, H., Jerkeman, M., Fosså, A., Andersson, T. M. L., Holte, H., Bøgsted, M., El-Galaly, T. C. & Smedby, K. E., 2019 mars 20, I: *Journal of Clinical Oncology*. 37, 9, s. 703-713 11 s.

**Adherence to the mediterranean diet and lymphoma risk in the european prospective investigation into cancer and nutrition**  
Solans, M., Benavente, Y., Saez, M., Agudo, A., Naudin, S., Hosnijeh, F. S., Noh, H., Freisling, H., Ferrari, P., Besson, C., Mahamat-Saleh, Y., Boutron-Ruault, M. C., Kühn, T., Kaaks, R., Boeing, H., Lasheras, C., Rodríguez-Barranco, M., Amiano, P., Huerta, J. M., Barricarte, A., & 26 andra Schmidt, J. A., Vineis, P., Riboli, E., Trichopoulou, A., Bamia, C., Peppas, E., Masala, G., Agnoli, C., Tumino, R., Sacerdote, C., Panico, S., Skeie, G., Weiderpass, E., Jerkeman, M., Ericson, U., Späth, F., Nilsson, L. M., Dahm, C. C., Overvad, K., Bolvig, A. K., Tjønneland, A., de Sanjose, S., Buckland, G., Vermeulen, R., Nieters, A. & Casabonne, D., 2019, I: *International Journal of Cancer*. 145, 1, s. 122-131

**Comparison of the NCCN-IPI, the IPI and PIT scores as prognostic tools in peripheral T-cell lymphomas**  
Ellin, F., Maurer, M. J., Srour, L., Farooq, U., Jerkeman, M., Connors, J. M., Smedby, K. E., Bennani, N. N., Ansell, S. M., Slack, G. W., Cerhan, J. R., Relander, T., Feldman, A. L. & Savage, K. J., 2019, I: *British Journal of Haematology*. 186, 3, s. e24-e27

Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs  
Matasar, M. J., Luminari, S., Barr, P. M., Barta, S. K., Danilov, A. V., Hill, B. T., Phillips, T. J., Jerkeman, M., Magagnoli, M., Nastoupil, L. J., Persky, D. O. & Okosun, J., 2019, I: *The Oncologist*. 24, 11, s. e1236-e1250

**Impact of comorbidity on disease characteristics, treatment intent and outcome in diffuse large B-cell lymphoma: a Swedish lymphoma register study**

Wästerlid, T., Mohammadi, M., Smedby, K. E., Glimelius, I., Jerkeman, M., Bottai, M. & Eloranta, S., 2019, I: *Journal of Internal Medicine*. 285, 4, s. 455-468

**Is there a role for immunomodulatory drugs in the treatment of mantle cell lymphoma?**

Albertsson-Lindblad, A. & Jerkeman, M., 2019, I: *Annals of Lymphoma*. 3, 2, s. 1-15

**Monitoring CAR-T-Cell Therapies Using the Nordic Healthcare Databases**

Callréus, T., El-Galaly, T. C., Jerkeman, M., de Nully Brown, P. & Andersen, M., 2019, I: *Pharmaceutical Medicine*. 33, 2, s. 83-88 6 s.

**Reproductive Factors, Exogenous Hormone Use, and Risk of B-Cell Non-Hodgkin Lymphoma in a Cohort of Women From the European Prospective Investigation Into Cancer and Nutrition**

Costas, L., Lujan-Barroso, L., Benavente, Y., Allen, N. E., Amiano, P., Ardanaz, E., Besson, C., Boeing, H., Bueno-de-Mesquita, B., Cervenka, I., Fortner, R. T., Fournier, A., Gunter, M., Harlid, S., Huerta, J. M., Jerkeman, M., Jirstrom, K., Kaaks, R., Karakatsani, A., Khaw, K. T., & 22 andraKotaniidou, A., Lund, E., Masala, G., Mattiello, A., Melin, B., Menéndez, V., Murphy, N., Nieters, A., Overvad, K., Riboli, E., Sacerdote, C., Sánchez, M. J., Schmidt, J. A., Sieri, S., Tjønneland, A., Trichopoulou, A., Tumino, R., Vermeulen, R., Weiderpass, E., de Sanjosé, S., Agudo, A. & Casabonne, D., 2019, I: *American Journal of Epidemiology*. 188, 2, s. 274-281 8 s.

**A platform for phenotypic discovery of therapeutic antibodies and targets applied on Chronic Lymphocytic Leukemia**

Ljungars, A., Mårtensson, L., Mattsson, J., Kovacek, M., Sundberg, A., Tornberg, U-C., Jansson, B., Persson, N., Emruli, V. K., Ek, S., Jerkeman, M., Hansson, M., Juliusson, G., Ohlin, M., Frendéus, B., Teige, I. & Mattsson, M., 2018 dec. 1, I: *JCO Precision Oncology*. 2, 1

**Body composition measurements and risk of hematological malignancies: A population-based cohort study during 20 years of followup**

Hagström, H., Andreasson, A., Carlsson, A. C., Jerkeman, M. & Carlsten, M., 2018 aug. 23, I: *PLoS ONE*. 13, 8, e0202651.

**Long-term survival and loss in expectancy of life in a population-based cohort of 7114 patients with diffuse large B-cell lymphoma**

Ekberg, S., Jerkeman, M., Andersson, P. O., Enblad, G., Wahlin, B. E., Hasselblom, S., Andersson, T. M., Eloranta, S. & Smedby, K. E., 2018 aug. 1, I: *American Journal of Hematology*. 93, 8, s. 1020-1028 9 s.

**Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study**

Rule, S., Jurczak, W., Jerkeman, M., Rusconi, C., Trneny, M., Offner, F., Caballero, D., Joao, C., Witzens-Harig, M., Hess, G., Bence-Bruckler, I., Cho, S. G., Thieblemont, C., Zhou, W., Henninger, T., Goldberg, J., Vermeulen, J. & Dreyling, M., 2018 aug., I: *Leukemia*. 32, 8, s. 1799-1803

**Valproate in combination with rituximab and CHOP as first-line therapy in diffuse large B-cell lymphoma (VALFRID)**

Drott, K., Hagberg, H., Papworth, K., Relander, T. & Jerkeman, M., 2018 juni 26, I: *Blood Advances*. 2, 12, s. 1386-1392 7 s.

**Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity**

Freiburghaus, C., Emruli, V. K., Johansson, A., Eskelund, C. W., Grønbæk, K., Olsson, R., Ek, F., Jerkeman, M. & Ek, S., 2018 apr. 25, I: *BMC Cancer*. 18, 1, 466.

**Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): A multicentre, open-label, single-arm, phase 2 trial**

Jerkeman, M., Eskelund, C. W., Hutchings, M., Rätty, R., Wader, K. F., Laurell, A., Toldbod, H., Pedersen, L. B., Niemann, C. U., Dahl, C., Kuitunen, H., Geisler, C. H., Grønnebæk, K. & Kolstad, A., 2018 mars, I: *The Lancet Haematology*. 5, 3, s. e109-e116

**Simplicity at the cost of predictive accuracy in diffuse large B-cell lymphoma: A critical assessment of the R-IPI, IPI, and NCCN-IPI**

Biccler, J., Eloranta, S., de Nully Brown, P., Frederiksen, H., Jerkeman, M., Smedby, K. E., Bøgsted, M. & El-Galaly, T. C., 2018 jan., I: *Cancer Medicine*. 7, 1, s. 114-122

**Impact of comorbidity on survival in peripheral T-cell lymphomas: A Swedish Lymphoma Registry study**

Ellin, F., Jerkeman, M., Törnqvist, J., Brudin, L. & Relander, T., 2018, I: *Hematological Oncology*. 36, 1, s. 159-165

**Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma**

Eskelund, C. W., Albertsson-Lindblad, A., Kolstad, A., Laurell, A., Rätty, R., Pedersen, L. B., Geisler, C. H., Jerkeman, M. & Grønnebæk, K., 2018, I: *Haematologica*. 103, 11, s. e541-e543

**Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma**

Dang, N. H., Ogura, M., Castaigne, S., Fayad, L. E., Jerkeman, M., Radford, J., Pezzutto, A., Bondarenko, I. N., Stewart, D. A., Shnaidman, M., Sullivan, S., Vandendries, E., Tobinai, K., Ramchandren, R., Hamlin, P. A., Giné, E. & Ando, K., 2018, I: *British Journal of Haematology*. 182, 4, s. 583-586

**Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations**

Dreyling, M., Aurer, I., Cortelazzo, S., Hermine, O., Hess, G., Jerkeman, M., Le Gouill, S., Ribrag, V., Trněný, M., Visco, C., Walewski, J., Zaja, F. & Zinzani, P. L., 2018, I: *Leukemia and Lymphoma*. 59, 8, s. 1814-1828

**International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma**

Maurer, M. J., Ellin, F., Srour, L., Jerkeman, M., Bennani, N. N., Connors, J. M., Slack, G. W., Smedby, K. E., Ansell, S. M., Link, B. K., Cerhan, J. R., Relander, T., Savage, K. J. & Feldman, A. L., 2017 dec. 20, I: *Journal of Clinical Oncology*. 35, 36, s. 4019-4026 8 s.

**Outcome of peripheral T-cell lymphoma in first complete remission: a Danish-Swedish population-based study**

Cederleuf, H., Hjort Jakobsen, L., Ellin, F., de Nully Brown, P., Stauffer Larsen, T., Bøgsted, M., Relander, T., Jerkeman, M. & El-Galaly, T. C., 2017 dec. 2, I: *Leukemia and Lymphoma*. 58, 12, s. 2815-2823 9 s.

**Crosstalk between ROR1 and BCR pathways defines novel treatment strategies in mantle cell lymphoma.**

Karvonen, H., Chiron, D., Niininen, W., Ek, S., Jerkeman, M., Moradi, E., Nykter, M., Heckman, C. A., Kallioniemi, O., Murumägi, A. & Ungureanu, D., 2017 nov. 9, I: *Blood Advances*. 1, 24, s. 2257-2268

**TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy**

Eskelund, C. W., Dahl, C., Hansen, J. W., Westman, M., Kolstad, A., Pedersen, L. B., Montano-Almendras, C. P., Husby, S., Freiburghaus, C., Ek, S., Pedersen, A., Niemann, C., Rätty, R., Brown, P., Geisler, C. H., Andersen, M. K., Guldborg, P., Jerkeman, M. & Grønnebæk, K., 2017 okt. 26, I: *Blood*. 130, 17, s. 1903-1910 8 s.

**Frequency and clinical implications of SOX11 expression in Burkitt lymphoma**

Wästerlid, T., Nordström, L., Freiburghaus, C., Pedersen, M., Nørgaard, P., Gang, A. O., Brown, P., Dictor, M., Jerkeman, M. & Ek, S., 2017, I: *Leukemia & Lymphoma*. 58, 7, s. 1760-1763 4 s.

**Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus**

Hess, G., Rule, S., Jurczak, W., Jerkeman, M., Santucci Silva, R., Rusconi, C., Caballero, D., Joao, C., Witzens-Harig, M., Bence-Bruckler, I., Cho, S-G., Zhou, W., Goldberg, J. D., Trambitas, C., Enny, C., Vermeulen, J., Traina, S., Chiou, C. F., Diels, J. & Dreyling, M., 2017, I: *Leukemia and Lymphoma*. 58, 12, s. 2824-2832



**Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years**  
Kolstad, A., Pedersen, L. B., Eskelund, C. W., Husby, S., Grønbæk, K., Jerkeman, M., Laurell, A., Rätty, R., Elonen, E., Andersen, N. S., Brown, P. D. N., Kimby, E., Bentzen, H., Sundström, C., Ehinger, M., Karjalainen-Lindsberg, M-L., Delabie, J., Ralfkiær, E., Fagerli, U-M., Nilsson-Ehle, H., & 4 andraLauritzsen, G. F., Kuittinen, O., Niemann, C. & Geisler, C. H., 2017, I: *Biology of Blood and Marrow Transplantation*. 23, 3, s. 428-435

**Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up**  
Dreyling, M., Campo, E., Hermine, O., Jerkeman, M., Le Gouill, S., Rule, S., Shpilberg, O., Walewski, J., Ladetto, M. & on behalf of the ESMO Guidelines Committee, 2017, I: *Annals of Oncology*. 28, s. iv62-iv71

**Targeting of B-cell receptor signalling in B-cell malignancies**

Jerkeman, M., Hallek, M., Dreyling, M., Thieblemont, C., Kimby, E. & Staudt, L., 2017, I: *Journal of Internal Medicine*. 282, 5, s. 415-428

**The addition of etoposide to CHOP is associated with improved outcome in ALK+ adult anaplastic large cell lymphoma: A Nordic Lymphoma Group study**

Cederleuf, H., Bjerregård Pedersen, M., Jerkeman, M., Relander, T., d'Amore, F. & Ellin, F., 2017, I: *British Journal of Haematology*. 178, 5, s. 739-746

**Plasma immunoprofiling of patients with high-risk diffuse large B-cell lymphoma: a Nordic Lymphoma Group study**

Pauly, F., Fjordén, K., Leppä, S., Holte, H., Björkholm, M., Fluge, Møller Pedersen, L., Eriksson, M., Isinger-Ekstrand, A., Borrebaeck, C. A. K., Jerkeman, M. & Wingren, C., 2016 nov. 18, I: *Blood Cancer Journal*. 6, 11, s. e501

**Chemotherapeutic intensity and survival differences in young patients with diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study**

Melén, C. M., Enblad, G., Sonnevi, K., Junlén, H. R., Smedby, K. E., Jerkeman, M. & Wahlin, B. E., 2016 nov. 1, I: *British Journal of Haematology*. 175, 4, s. 614-622 9 s.

**Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration**

Cheah, C. Y., Bröckelmann, P. J., Chihara, D., Moskowitz, A. J., Engert, A., Jerkeman, M., El-Galaly, T. C., Augustson, B., Vose, J., Bartlett, N. L., Villa, D., Connors, J. M., Feldman, T., Pinnix, C. C., Milgrom, S. A., Dabaja, B., Oki, Y. & Fanale, M. A., 2016 sep. 1, I: *American Journal of Hematology*. 91, 9, s. 894-899 6 s.

**Lenalidomide-bendamustine-rituximab in untreated mantle cell lymphoma > 65 years, the Nordic Lymphoma Group phase I+II trial NLG-MCL4**

Albertsson-Lindblad, A., Kolstad, A., Laurell, A., Rätty, R., Grønbæk, K., Sundberg, J., Pedersen, L. B., Ralfkiær, E., Karjalainen-Lindsberg, M-L., Sundström, C., Ehinger, M., Geisler, C. & Jerkeman, M., 2016 juni 27, I: *Blood*. 128, 14, s. 1814-1820

**15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): Prolonged remissions without survival plateau**

Eskelund, C. W., Kolstad, A., Jerkeman, M., Rätty, R., Laurell, A., Eloranta, S., Smedby, K. E., Husby, S., Pedersen, L. B., Andersen, N. S., Eriksson, M., Kimby, E., Bentzen, H., Kuittinen, O., Lauritzsen, G. F., Nilsson-Ehle, H., Ralfkiær, E., Ehinger, M., Sundström, C., Delabie, J., & 7 andraKarjalainen-Lindsberg, M. L., Workman, C. T., Garde, C., Elonen, E., Brown, P., Grønbæk, K. & Geisler, C. H., 2016, I: *British Journal of Haematology*. 175, 3, s. 410-418

**Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.**

Dreyling, M., Jurczak, W., Jerkeman, M., Silva, R. S., Rusconi, C., Trneny, M., Offner, F., Caballero, D., Joao, C., Witzens-Harig, M., Hess, G., Bence-Bruckler, I., Cho, S-G., Bothos, J., Goldberg, J. D., Enny, C., Traina, S., Balasubramanian, S., Bandyopadhyay, N., Sun, S., & 3 andraVermeulen, J., Rizo, A. & Rule, S., 2016, I: *The Lancet*. 387, 10020, s. 770-778

**No survival benefit associated with routine surveillance imaging for Hodgkin lymphoma in first remission: a Danish-Swedish population-based observational study.**

Jakobsen, L. H., Hutchings, M., de Nully Brown, P., Linderöth, J., Mylam, K. J., Molin, D., Johnsen, H. E., Bøgsted, M., Jerkeman, M. & El-Galaly, T. C., 2016, I: *British Journal of Haematology*.

**Season of diagnosis is associated with overall survival in patients with diffuse large B-cell lymphoma but not with Hodgkin's lymphoma - A population-based Swedish Lymphoma Register study.**

SZENTKIRALYI SZEKELY, ERZSÉBET., Lindén, O., Peterson, S. & Jerkeman, M., 2016, I: *European Journal of Haematology*. 97, 4, s. 393–398

**Antagonistic Human FcγRIIB (CD32B) Antibodies Have Anti-Tumor Activity and Overcome Resistance to Antibody Therapy In Vivo.**

Roghianian, A., Teige, I., Mårtensson, L., Cox, K. L., Kovacek, M., Ljungars, A., Mattson, J., Sundberg, A., Vaughan, A. T., Shah, V., Smyth, N. R., Sheth, B., Chan, H. T. C., Li, Z-C., Williams, E. L., Manfredi, G., Oldham, R. J., Mockridge, C. I., James, S. A., Dahal, L. N., & 12 andra Hussain, K., Nilsson, B., Verbeek, J. S., Juliusson, G., Hansson, M., Jerkeman, M., Johnson, P. W. M., Davies, A., Beers, S. A., Glennie, M. J., Frendeus, B. & Cragg, M. S., 2015, I: *Cancer Cell*. 27, 4, s. 473-488

**Central nervous system relapse in peripheral T-cell lymphomas: A Swedish lymphoma registry study.**

Ellin, F., Landström, J., Jerkeman, M. & Relander, T., 2015, I: *Blood*. 126, 1, s. 36-41

**Emerging role of SOX11 in mantle cell lymphoma**

Kuci, V., Nordström, L., Jerkeman, M. & Ek, S., 2015, I: *Blood and Lymphatic Cancer: Targets and Therapy*. 5, s. 35-41

**Impact on survival of addition of etoposide to primary chemotherapy in diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study.**

Wästerlid, T., Werner Hartman, L., Szekely, E. & Jerkeman, M., 2015, I: *Hematological Oncology*.

**Long-term remission in idiopathic Castleman's disease with tocilizumab followed by consolidation with high-dose melphalan-two case studies.**

Jerkeman, M. & Lindén, O., 2015, I: *European Journal of Haematology*.

**Long-term survival in young and middle-aged Hodgkin lymphoma patients in Sweden 1992-2009 - trends in cure proportions by clinical characteristics.**

Glimelius, I., Ekberg, S., Jerkeman, M., Chang, E. T., Björkholm, M., Andersson, T. M. L., Smedby, K. E. & Eloranta, S., 2015, I: *American Journal of Hematology*. 90, 12, s. 1128-1134

**Low RBM3 Protein Expression Correlates with Clinical Stage, Prognostic Classification and Increased Risk of Treatment Failure in Testicular Non-Seminomatous Germ Cell Cancer.**

Olofsson, S-E., Nodin, B., Gaber, A., Eberhard, J., Uhlén, M., Jirstrom, K. & Jerkeman, M., 2015, I: *PLoS ONE*. 10, 3, e0121300.

**Male gender is an adverse risk factor only in young patients with diffuse large B-cell lymphoma - a Swedish population-based study**

Hedstrom, G., Peterson, S., Berglund, M., Jerkeman, M. & Enblad, G., 2015, I: *Acta Oncologica*. 54, 6, s. 924-932

**miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator.**

Husby, S., Ralfkiaer, U., Garde, C., Zandi, R., Ek, S., Kolstad, A., Jerkeman, M., Laurell, A., Rätty, R., Pedersen, L. B., Pedersen, A., Ehinger, M., Sundström, C., Karjalainen-Lindsberg, M-L., Delabie, J., Clasen-Linde, E., Brown, P., Cowland, J., Workman, C. T., Geisler, C. H., & 1 andra Grønnebæk, K., 2015, I: *Blood*. 125, 17, s. 2669-2677

**Pharmacologically relevant doses of valproate upregulate CD20 expression in three diffuse large B-cell lymphoma patients in vivo.**

Kofoed Damm, J., Gordon, S., Ehinger, M., Jerkeman, M., Gullberg, U., Hultquist, A. & Drott, K., 2015, I: *Experimental hematology & oncology*. 4, 4

**Routine Imaging for Diffuse Large B-Cell Lymphoma in First Complete Remission Does Not Improve Post-Treatment Survival: A Danish-Swedish Population-Based Study.**

El-Galaly, T. C., Jakobsen, L. H., Hutchings, M., de Nully Brown, P., Nilsson-Ehle, H., Szekely, E., Mylam, K. J., Hjalmar, V., Johnsen, H. E., Bøgsted, M. & Jerkeman, M., 2015, I: *Journal of Clinical Oncology*. 33, 34, s. 3993-3998

**Sick leave and disability pension among Swedish testicular cancer survivors according to clinical stage and treatment**

Nord, C., Olofsson, S-E., Glimelius, I., Cedermark, G. C., Ekberg, S., Cavallin-Ståhl, E., Neovius, M., Jerkeman, M. & Smedby, K. E., 2015, I: *Acta Oncologica*. 54, 10, s. 1770-1780

**Sick leave and disability pension in Hodgkin lymphoma survivors by stage, treatment, and follow-up time-a population-based comparative study**

Glimelius, I., Ekberg, S., Linderöth, J., Jerkeman, M., Chang, E. T., Neovius, M. & Smedby, K. E., 2015, I: *Journal of Cancer Survivorship*. 9, 4, s. 599-609

**The impact of age on survival of diffuse large B-cell lymphoma - a population-based study**

Hedstrom, G., Hagberg, O., Jerkeman, M. & Enblad, G., 2015, I: *Acta Oncologica*. 54, 6, s. 916-923

**Total body irradiation after high-dose cytarabine in mantle cell lymphoma: A comparison of Nordic MCL2, HOVON-45, and European MCL Younger trials.**

Hoster, E., Geisler, C. H., Doorduijn, J., van der Holt, B., Walewski, J., Bloehdorn, J., Ribrag, V., Salles, G., Hallek, M., Pott, C., Szymczyk, M., Kolstad, A., Laurell, A., Rätty, R., Jerkeman, M., Van't Veer, M., Kluin-Nelemans, J. C., Klapper, W., Unterhalt, M., Dreyling, M., & 1 andraHermine, O., 2015, I: *Leukemia*.

**Update on the molecular pathogenesis and targeted approaches of mantle cell lymphoma: summary of the 12th annual conference of the European Mantle Cell Lymphoma Network**

Dreyling, M., Amador, V., Callanan, M., Jerkeman, M., Le Gouli, S., Pott, C., Rule, S. & Zaja, F., 2015, I: *Leukemia & Lymphoma*. 56, 4, s. 866-876

**Deregulation of COMMD1 Is Associated with Poor Prognosis in Diffuse Large B-cell Lymphoma.**

Taskinen, M., Louhimo, R., Koivula, S., Chen, P., Rantanen, V., Holte, H., Delabie, J., Karjalainen-Lindsberg, M-L., Björkholm, M., Fluge, O., Pedersen, L. M., Fjordén, K., Jerkeman, M., Eriksson, M., Hautaniemi, S. & Leppä, S., 2014, I: *PLoS ONE*. 9, 3, e91031.

**High dose cytarabine with rituximab is not enough in first-line treatment of mantle cell lymphoma with high proliferation: early closure of the Nordic Lymphoma Group Mantle Cell Lymphoma 5 trial**

Laurell, A., Kolstad, A., Jerkeman, M., Raty, R. & Geisler, C. H., 2014, I: *Leukemia & Lymphoma*. 55, 5, s. 1206-1208

**Identification of B-cell lymphoma subsets by plasma protein profiling using recombinant antibody microarrays.**

Pauly, F., Smedby, K. E., Jerkeman, M., Hjalgrim, H., Ohlsson, M., Rosenquist, R., Borrebaeck, C. A. K. & Wingren, C., 2014, I: *Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis*. 38, 6, s. 682-690

**Improvement in survival of diffuse large B-cell lymphoma in relation to age, gender, International Prognostic Index and extranodal presentation: a population based Swedish Lymphoma Registry study**

Szekely, E., Hagberg, O., Arnljots, K. & Jerkeman, M., 2014, I: *Leukemia & Lymphoma*. 55, 8, s. 1838-1843

**Nordic MCL3 study: Y-90-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma**

Kolstad, A., Laurell, A., Jerkeman, M., Gronbaek, K., Elonen, E., Raty, R., Pedersen, L. B., Loft, A., Bogsrud, T. V., Kimby, E., Hansen, P. B., Fagerli, U-M., Nilsson-Ehle, H., Lauritzsen, G. F., Lehmann, A. K., Sundstrom, C., Karjalainen-Lindsberg, M-L., Ralfkiaer, E., Ehinger, M., Delabie, J., & 6 andraBentzen, H., Schildt, J., Kostova-Aherdan, K., Frederiksen, H., Brown, P. D. N. & Geisler, C. H., 2014, I: *Blood*. 123, 19, s. 2953-2959

**Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study.**

Abrahamsson, A., Albertsson Lindblad, A., Brown, P. N., Baumgartner-Wennerholm, S., Pedersen, L. M., D'Amore, F., Nilsson-Ehle, H., Jensen, P., Pedersen, M., Geisler, C. H. & Jerkeman, M., 2014, I: *Blood*. 124, 8, s. 1288-1295

**Real world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry.**

Ellin, F., Landström, J., Jerkeman, M. & Relander, T., 2014, I: Blood. 124, 10, s. 1570-1577

**SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma - a Nordic Lymphoma Group study.**

Nordström, L., Sernbo, S., Eden, P., Grønbaek, K., Kolstad, A., Rätty, R., Karjalainen, M-L., Geisler, C., Ralfkiaer, E., Sundström, C., Laurell, A., Delabie, J., Ehinger, M., Jerkeman, M. & Ek, S., 2014, I: British Journal of Haematology. 166, 1, s. 98-108

**Treatment outcome in T-cell lymphoblastic lymphoma in adults - a population-based study from the Swedish Lymphoma Registry**

Ellin, F., Jerkeman, M., Hagberg, H. & Relander, T., 2014, I: Acta Oncologica. 53, 7, s. 927-934

**Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study**

Holte, H., Leppa, S., Bjorkholm, M., Fluge, O., Jyrkkio, S., Delabie, J., Sundstrom, C., Karjalainen-Lindsberg, M. -L., Erlanson, M., Kolstad, A., Fossa, A., Ostenstad, B., Lofvenberg, E., Nordstrom, M., Janes, R., Pedersen, L. M., Anderson, H., Jerkeman, M. & Eriksson, M., 2013, I: Annals of Oncology. 24, 5, s. 1385-1392

**Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group.**

Wästerlid, T., Brown, P. N., Hagberg, O., Hagberg, H., Pedersen, L. M., D'Amore, F. & Jerkeman, M., 2013, I: Annals of Oncology. 24, 7, s. 1879-1886

**Expanded clinical and experimental use of SOX11-using a monoclonal antibody**

Nordström, L., Andreasson, U., Jerkeman, M., Dictor, M., Borrebaeck, C. & Ek, S., 2012, I: BMC Cancer. 12, 269

**Gene expression profiling indicates that immunohistochemical expression of CD40 is a marker of an inflammatory reaction in the tumor stroma of diffuse large B-cell lymphoma**

Fjordén, K., Joost, P., Ehinger, M., Edén, P., Jerkeman, M., Cavallin-Ståhl, E. & Linderöth, J., 2012, I: Leukemia & Lymphoma. 53, 9, s. 1764-1768

**High serum vascular endothelial growth factor level is an adverse prognostic factor for high-risk diffuse large B-cell lymphoma patients treated with dose-dense chemoimmunotherapy**

Riihijarvi, S., Nurmi, H., Holte, H., Bjorkholm, M., Fluge, O., Pedersen, L. M., Fjordén, K., Jerkeman, M., Eriksson, M. & Leppa, S., 2012, I: European Journal of Haematology. 89, 5, s. 395-402

**Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC plus autologous stem-cell support: still very long survival but late relapses do occur**

Geisler, C. H., Kolstad, A., Laurell, A., Jerkeman, M., Rätty, R., Andersen, N. S., Pedersen, L. B., Eriksson, M., Nordstrom, M., Kimby, E., Bentzen, H., Kuittinen, O., Lauritzsen, G. F., Nilsson-Ehle, H., Ralfkiaer, E., Ehinger, M., Sundstrom, C., Delabie, J., Karjalainen-Lindsberg, M-L., Brown, P., & 1 andraElonen, E., 2012, I: British Journal of Haematology. 158, 3, s. 355-362

**Inhibition of geranylgeranylation mediates sensitivity to CHOP-induced cell death of DLBCL cell lines.**

Ageberg, M., Fjordén, K., Lindén, O., Linderöth, J., Jerkeman, M. & Drott, K., 2011, I: Experimental Cell Research. 317, s. 1179-1191

**Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy**

Riihijarvi, S., Taskinen, M., Jerkeman, M. & Leppa, S., 2011, I: European Journal of Haematology. 86, 2, s. 124-128

**Marked improvement of overall survival in mantle cell lymphoma: a population based study from the Swedish Lymphoma Registry.**

Abrahamsson, A., Dahle, N. & Jerkeman, M., 2011, I: Leukemia & Lymphoma. 52, 10, s. 1929-1935

**Nordic MCL2 Trial of 1st-Line Intensive Immunochemotherapy and Autologous Stem Cell Transplantation in Mantle Cell Lymphoma: Still Encouraging Results After Median 5½ Years Observation Time**

Geisler, C. H., Kolstad, A., Laurell, A., Raty, R., Jerkeman, M., Eriksson, M., Nordstrom, M., Kimby, E., Bentzen, H. E. N., Nilsson-Ehle, H., Kuittinen, O., Lauritzsen, G. F., Ralfkiaer, E., Ehinger, M., Sundstrom, C., Delabie, J., Karjalainen-Lindsberg, M. -L., Pedersen, L. B., Andersen, N. S., Brown, P. D. N., & 1 andraElonen, E., 2011, I: *Biology of Blood and Marrow Transplantation*. 17, 2, s. 196-196

**Population based study of prognostic factors and treatment in adult Burkitt lymphoma: a Swedish Lymphoma Registry study.**

Wästerlid, T., Jonsson, B., Hagberg, H. & Jerkeman, M., 2011, I: *Leukemia & Lymphoma*. 52, 11, s. 2090-2096

**Population-Based Study of Treatment Guided by Tumor Marker Decline in Patients With Metastatic Nonseminomatous Germ Cell Tumor: A Report From the Swedish-Norwegian Testicular Cancer Group.**

Olofsson, S-E., Tandstad, T., Jerkeman, M., Dahl, O., Ståhl, O., Klepp, O., Bremnes, R. M., Cohn-Cedermark, G., Langberg, C. W., Laurell, A., Solberg, A., Stierner, U., Wahlqvist, R., Wijkström, H., Anderson, H. & Cavallin-Ståhl, E., 2011, I: *Journal of Clinical Oncology*. 29, s. 2032-2039

**CD40 is a potential marker of favorable prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.**

Fjordén, K., Linderöth, J., Nyman, H., Ehinger, M., Joost, P., Bendahl, P-O., Leppä, S. & Jerkeman, M., 2010, I: *Leukemia & Lymphoma*. 51, s. 1643-1648

**Exon Based Transcriptome Profiling Reveals Genes That Have Prognostic Impact on the Survival of Young High Risk Diffuse Large B Cell/Follicular Grade 3 Lymphoma Patients Treated with Dose Dense Chemoimmunotherapy and CNS Prophylaxis Results From a Nordic Lymphoma Group Phase II Study**

Koivula, S., Taskinen, M., Chen, P., Holte, H., Delabie, J., Lindsberg, M. L. K., Bjorkholm, M., Fluge, O., Pedersen, L. M., Jerkeman, M., Eriksson, M., Hautaniemi, S. & Leppä, S., 2010, I: *Blood*. 116, 21, s. 1281-1281

**High Serum Vascular Endothelial Growth Factor (VEGF) Level Is An Adverse Prognostic Factor In High Risk Diffuse Large B Cell Lymphoma (DLBCL) Patients Treated with Dose Dense Chemoimmunotherapy and Systemic CNS Prophylaxis Results From a Nordic Phase II Study**

Riihajarvi, S., Nyman, H., Holte, H., Bjorkholm, M., Fluge, O., Pedersen, L. M., Jerkeman, M., Eriksson, M. & Leppä, S., 2010, I: *Blood*. 116, 21, s. 1686-1686

**Identification of uniquely expressed transcription factors in highly purified B-cell lymphoma samples.**

Andreasson, U., Edén, P., Peterson, C., Högerkorp, C-M., Jerkeman, M., Andersen, N., Berglund, M., Sundström, C., Rosenquist, R., Borrebaeck, C. & Ek, S., 2010, I: *American Journal of Hematology*. 85, 6, s. 418-425

**Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma**

d'Amore, F., Radford, J., Relander, T., Jerkeman, M., Tilly, H., Osterborg, A., Morschhauser, F., Gramatzki, M., Dreyling, M., Bang, B. & Hagberg, H., 2010, I: *British Journal of Haematology*. 150, 5, s. 565-573

**Prognostic impact of protein kinase C beta II expression in R-CHOP-treated diffuse large B-cell lymphoma patients**

Riihajarvi, S., Koivula, S., Nyman, H., Fjordén, K., Jerkeman, M. & Leppä, S., 2010, I: *Modern Pathology*. 23, 5, s. 686-693

**SOX11 expression correlates to promoter methylation and regulates tumor growth in hematopoietic malignancies**

Gustavsson, E., Sernbo, S., Andersson, E., Brennan, D., Dictor, M., Jerkeman, M., Borrebaeck, C. & Ek, S., 2010, I: *Molecular Cancer*. 9, 187

**The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)**

Geisler, C. H., Kolstad, A., Laurell, A., Raty, R., Jerkeman, M., Eriksson, M., Nordstrom, M., Kimby, E., Boesen, A. M., Nilsson-Ehle, H., Kuittinen, O., Lauritzsen, G. F., Ralfkiaer, E., Ehinger, M., Sundstrom, C., Delabie, J., Karjalainen-Lindsberg, M-L., Brown, P. & Elonen, E., 2010, I: *Blood*. 115, 8, s. 1530-1533

**(90)y-Ibritumumab Tiuxetan (Zevalin (R))-BEAM/C with Autologous Stem Cell Support as Frontline Therapy for Advanced Mantle Cell Lymphoma.- Preliminary Results From the Third Nordic MCL Phase II Study (MCL3)**

Kolstad, A., Laurell, A., Andersen, N. S., Elonen, E., Raty, R., Pedersen, L. B., Loft, A., Bogsrud, T. V., Nordstrom, M., Gillstrom, D., Hansen, P. B., Bentzen, H., Fagerli, U-M., Meyer, P., Nilsson-Ehle, H., Jerkeman, M., Lehmann, A. K., Lauritzsen, G. F., Sundstrom, C., Delabie, J., & 4 andraKarjalainen-Lindsberg, M-L., Ralfkiaer, E., Ehinger, M. & Geisler, C. H., 2009, I: Blood. 114, 22, s. 384-384

**Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas**

Nyman, H., Jerkeman, M., Karjalainen-Lindsberg, M-L., Banham, A. H., Enblad, G. & Leppa, S., 2009, I: European Journal of Haematology. 82, 5, s. 364-372

**Identification of molecular targets associated with transformed diffuse large B cell lymphoma using highly purified tumor cells.**

Andreasson, U., Dictor, M., Jerkeman, M., Berglund, M., Sundström, C., Linderöth, J., Rosenquist, R., Borrebaeck, C. & Ek, S., 2009, I: American Journal of Hematology. 84, s. 803-808

**Individualized intensification of treatment based on tumor marker decline in metastatic nonseminomatous germ cell testicular cancer (NSGCT): A report from the Swedish Norwegian Testicular Cancer Group, SWENOTECA**

Olofsson, S., Dahl, O., Jerkeman, M., Cohn-Cedermark, G., Klepp, O., Stierner, U., Tornblom, M., Wahlqvist, R. & Cavallin-Ståhl, E., 2009, I: Journal of Clinical Oncology. 27, 15

**Pre-Emptive Treatment With Rituximab of Molecular Relapse After Autologous Stem Cell Transplantation in Mantle Cell Lymphoma.**

Andersen, N. S., Pedersen, L. B., Laurell, A., Elonen, E., Kolstad, A., Boesen, A. M., Pedersen, L. M., Lauritzsen, G. F., Ekanger, R., Nilsson-Ehle, H., Nordström, M., Fredén, S., Jerkeman, M., Eriksson, M., Väärt, J., Malmer, B. & Geisler, C. H., 2009, I: Journal of Clinical Oncology. 27, s. 4365-4370

**Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP**

Nyman, H., Jerkeman, M., Karjalainen-Lindsberg, M-L., Banham, A. H. & Leppa, S., 2009, I: Modern Pathology. 22, 8, s. 1094-1101

**B cell lymphomas express CX(3)CR1 a non-B cell lineage adhesion molecule.**

Andreasson, U., Ek, S., Merz, H., Rosenquist, R., Andersen, N., Jerkeman, M., Dictor, M. & Borrebaeck, C. A. K., 2008, I: Cancer Letters. 259, 2, s. 138-145

**BCL-2 but not FOXP1, is an adverse risk factor in immunochemotherapy treated non-germinal center diffuse large B-cell lymphomas**

Nyman, H., Jerkeman, M., Karjalainen-Lindsberg, M., Banham, A., Enblad, G. & Leppa, S., 2008, I: Annals of Oncology. 19, Suppl. 4, s. iv 142-iv 142

**Burkitt's lymphoma: Comparison of 2 nationwide population-based lymphoma registries**

Brown, P. D., Samuelsson, V., d'Amore, F., Lindh, J., Hagberg, H., Nilsson, G., Bernell, P., Pedersen, L. M. & Jerkeman, M., 2008, I: Annals of Oncology. 19, Suppl. 4, s. iv 131-iv 131

**Genes associated with the tumour microenvironment are differentially expressed in cured versus primary chemotherapy-refractory diffuse large B-cell lymphoma.**

Linderöth, J., Edén, P., Ehinger, M., Valcich, J., Jerkeman, M., Bendahl, P-O., Berglund, M., Enblad, G., Erlanson, M., Roos, G. & Cavallin-Ståhl, E., 2008, I: British Journal of Haematology. 141, 4, s. 423-432

**Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group**

Geisler, C. H., Kolstad, A., Laurell, A., Andersen, N. S., Pedersen, L. B., Jerkeman, M., Eriksson, M., Nordstrom, M., Kimby, E., Boesen, A. M., Kuittinen, O., Lauritzsen, G. F., Nilsson-Ehle, H., Ralfkiaer, E., Åkerman, M., Ehinger, M., Sundstrom, C., Langholm, R., Delabie, J., Karjalainen-Lindsberg, M-L., & 2 andraBrown, P. & Elonen, E., 2008, I: Blood. 112, 7, s. 2687-2693

**Nuclear expression of the Non-B Cell Lineage Sox11 Transcription Factor Identifies Mantle Cell Lymphoma**  
Ek, S., Dictor, M., Jerkeman, M., Jirström, K. & Borrebaeck, C., 2008, I: *Blood*. 111, 2, s. 800-805

**R-CHOEP-14 X 6 Followed by Systemic CNS Prophylaxis for Diffuse Large B-Cell Lymphoma (DLBCL)/Follicular Lymphoma (FL) Grade 3 with Age Adjusted IPI Score 2-3: Preliminary Results of a Nordic Lymphoma Group (NLG) Phase 2 Study Including 160 Patients Aged 18-64 Years.**

Holte, H., Leppa, S. M., Bjorkholm, M., Fluge, O., Jyrkkio, S., Delabie, J., Sundstrom, C., Karjalainen-Lindsberg, M-L., Erlanson, M., Kolstad, A., Fossa, A., Ostenstad, B., Lofvenberg, E., Nordstroem, M., Moller-Pedersen, L., Anderson, H., Jerkeman, M. & Eriksson, M., 2008, I: *Blood*. 112, 11, s. 1233-1233

**Sox11, a non-B cell lineage transcription factor, is overexpressed in mantle cell lymphoma**

Dictor, M., Ek, S., Jerkeman, M., Jirström, K. & Borrebaeck, C., 2008, I: *Annals of Oncology*. 19, Suppl. 4, s. iv 172-iv 173

**Transformed diffuse large B cell lymphomas differ from follicular lymphomas in both gene and protein expression**

Andreasson, U., Dictor, M., Jerkeman, M., Rosenquist, R., Borrebaeck, C. & Ek, S., 2008, I: *Annals of Oncology*. 19, Suppl. 4, s. iv 111-iv 111

**Biphenotypic bigenotypic lymphoma with simultaneous expression of PAX5/BSAP and B- and T-cell markers**

Hansson, M., Jerkeman, M. & Dictor, M., 2007, I: *European Journal of Haematology*. 79, 2, s. 159-165

**CD40 expression identifies a prognostically favourable subgroup of diffuse large B-cell lymphoma.**

Linderth, J., Ehinger, M., Jerkeman, M., Bendahl, P-O., Åkerman, M., Berglund, M., Enblad, G., Erlanson, M., Roos, G. & Cavallin-Ståhl, E., 2007, I: *Leukemia & Lymphoma*. 48, 9, s. 1774-1779

**Protein expression and cellular localization in two prognostic subgroups of diffuse large B-cell lymphoma: Higher expression of ZAP70 and PKC-beta II in the non-germinal center group and poor survival in patients deficient in nuclear PTEN**

Fridberg, M., Servin, A., Anagnostaki, L., Linderth, J., Berglund, M., Soderberg, O., Enblad, G., Rosen, A., Mustelin, T., Jerkeman, M., Persson, J. L. & Gjörlöf Wingren, A., 2007, I: *Leukemia & Lymphoma*. 48, 11, s. 2221-2232

**Tissue microarray is inappropriate for analysis of BCL6 expression in diffuse large B-cell lymphoma.**

Linderth, J., Ehinger, M., Åkerman, M., Cavallin-Ståhl, E., Enblad, G., Erlanson, M. & Jerkeman, M., 2007, I: *European Journal of Haematology*. 79, 2, s. 146-149

**Midline carcinoma with t(15;19) and BRD4-NUT fusion oncogene in a 30-year-old female with response to docetaxel and radiotherapy**

Engleson, J., Soller, M., Panagopoulos, I., Dahlen, A., Dictor, M. & Jerkeman, M., 2006, I: *BMC Cancer*. 6

**Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis**

Berglund, M., Thunberg, U., Amini, R.M., Book, M., Roos, G., Erlanson, M., Linderth, J., Dictor, M., Jerkeman, M., Cavallin-Ståhl, E., Sundstrom, C., Rehn-Eriksson, S., Backlin, C., Hagberg, H., Rosenquist, R. & Enblad, G., 2005, I: *Modern Pathology*. 18, 8, s. 1113-1120

**High expression of cyclin B1 predicts a favorable outcome in patients with follicular lymphoma**

Bjorck, E., Ek, S., Landgren, O., Jerkeman, M., Ehinger, M., Bjorkholm, M., Borrebaeck, C., Porwit-MacDonald, A. & Nordenskjöld, M., 2005, I: *Blood*. 105, 7, s. 2908-2915

**Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma—a Nordic Lymphoma Group study.**

Jerkeman, M., Anderson, H., Dictor, M., Kvaløy, S., Åkerman, M. & Cavallin-Ståhl, E., 2004, I: *Annals of Hematology*. 83, 7, s. 414-419

**ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma—the Nordic Lymphoma Group experience.**

Jerkeman, M., Leppä, S., Kvaløy, S. & Holte, H., 2004, I: *European Journal of Haematology*. 73, 3, s. 179-182

**Immunohistochemical Expression of CD23 and CD40 May Identify Prognostically Favorable Subgroups of Diffuse Large B-cell Lymphoma: A Nordic Lymphoma Group Study.**

Linderth, J., Jerkeman, M., Cavallin-Ståhl, E., Kvaløy, S. & Torlakovic, E., 2003, I: *Clinical Cancer Research*. 9, 2, s. 722-728

**Prognostic implications of BCL6 rearrangement in uniformly treated patients with diffuse large B-cell lymphoma—a Nordic Lymphoma Group study.**

Jerkeman, M., Aman, P., Cavallin-Ståhl, E., Torlakovic, E., Åkerman, M., Mitelman, F. & Fioretos, T., 2002, I: *International Journal of Oncology*. 20, 1, s. 161-165

**Expression of the B-cell transcription factor PU.1 is strongly correlated with CD10, CD79a, CD20, CD22, and bcl-6 expression in diffuse large B-cell lymphoma (DLBCL)**

Torlakovic, E., Linderth, J., Jerkeman, M., Kvaløy, S. & Delabie, J., 2001, I: *Blood*. 98, 11, s. 330A-330A

**Health-related quality of life and its potential prognostic implications in patients with aggressive lymphoma: a Nordic Lymphoma Group Trial**

Jerkeman, M., Kaasa, S., Hjermland, M., Kvaløy, S. & Cavallin-Ståhl, E., 2001, I: *Medical Oncology*. 18, 1, s. 85-94

**Survival in patients with intermediate or high grade non-Hodgkin's lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP**

Messori, A., Vaiani, M., Trippoli, S., Rigacci, L., Jerkeman, M. & Longo, G., 2001, I: *British Journal of Cancer*. 84, 3, s. 303-307

**Aggressive lymphoma**

Jerkeman, M., 2000, Department of Oncology, Clinical Sciences, Lund University. 149 s.

**Residual mass in aggressive lymphoma—does size, measured by computed tomography, influence clinical outcome?**

Rodriguez-Catarino, M., Jerkeman, M., Ahlstrom, H., Glimelius, B. & Hagberg, H., 2000, I: *Acta Oncologica*. 39, 4, s. 485-489

**CHOP versus MACOP-B in aggressive lymphoma—a Nordic Lymphoma Group randomised trial**

Jerkeman, M., Anderson, H., Cavallin-Ståhl, E., Dictor, M., Hagberg, H., Johnson, A., Kaasa, S., Kvaløy, S., Sundstrom, C. & Åkerman, M., 1999, I: *Annals of Oncology*. 10, 9, s. 1079-1086

**Prognostic implications of cytogenetic aberrations in diffuse large B-cell lymphomas**

Jerkeman, M., Johansson, B., Åkerman, M., Cavallin-Ståhl, E., Kristoffersson, U. & Mitelman, F., 1999, I: *European Journal of Haematology*. 62, 3, s. 184-190

**Bacteremic and non-bacteremic febrile urinary tract infection—a review of 168 hospital-treated patients**

Jerkeman, M. & Braconier, J. H., 1992, I: *Infection*. 20, 3, s. 143-145